A Phase I/II, Clinical Trial to Evaluate the Safety and Immune Activation of the Combination of DCVAC/PCa, and ONCOS-102, in Men With Advanced Metastatic Castration-resistant Prostate Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2019
Price : $35 *
At a glance
- Drugs ONCOS 102 (Primary) ; Stapuldencel-T (Primary) ; Cyclophosphamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 12 Jul 2018 According to a SOTIO media release, the first patient has been dosed at the Motol University Hospital by the principal investigator Dr. Ladislav Jarolim. One additional trial site is planned to be opened in the UK later in 2018.
- 24 May 2018 According to a SOTIO media release, the first patient has been enrolled in this trial by the principal investigator Dr. Ladislav Jarolim at Motol University Hospital (Czech Republic).
- 04 May 2018 New trial record